Abiomed Announces Schedule for TCT 2007 Global Live Broadcasts of Impella(R) 2.5 Patient Procedures.

WASHINGTON -- Abiomed, Inc. (NASDAQ: ABMD), today announced its planned schedule for the global live broadcasts of Impella 2.5 patient procedures at the Cardiovascular Research Foundation's (CRF) annual Transcatheter Cardiovascular Therapeutics (TCT) scientific meeting, scheduled from Saturday, October 20 until Thursday, October 25, in Washington, D.C.

The current schedule of live Impella 2.5 patient procedures to be broadcast at TCT from hospitals in the U.S., Germany, France and India are as follows (times are estimated U.S. ET):

Tuesday, October 23, 2007
8:00 a.m.        Columbia University Medical Center, New York, NY,
                 Main Arena, Ballrooms ABC, Level 3, Plenary Session
                 9: Live Case, Session III

Wednesday, October 24, 2007
8:30 a.m.        HELIOS Heart Center, Siegburg, Germany, Coronary
                 Theatre, Lower Level, JIM, Special Session, Live Case
                 Session V

11:30 a.m.       Institut Hospitalier Jacques Cartier, Massy, France,
                 Coronary Theatre, Lower Level, JIM, Special Session,
                 Live Case Session VI

4:30 p.m.        Max Heart and Vascular Institute, New Delhi, India,
                 Coronary Theatre, Lower Level, JIM, Special Session,
                 Live Case Session VII: Unusual Cases

All live case procedures will be simultaneously transmitted and broadcast at Abiomed's booth, 6121. The schedule of live case broadcasts is subject to change. All U.S. live cases have been approved under U.S. regulatory guidelines and limitations.

Additionally, Abiomed will make the first public announcement of the results of the PROTECT I Impella safety trial at the TCT Symposium entitled, "Impella: Redefining the Standard of Circulatory Support for Acute Heart Failure," chaired by William O'Neill, M.D., National Principal Investigator for the pilot and pivotal studies of the Impella 2.5, and Professor and Executive Dean for Clinical Affairs, Division of Cardiology at the Leonard M. Miller School of Medicine at the University of Miami, in the Renaissance Ballroom of the Renaissance Hotel on Sunday, October 21. The reception begins at 7:30 p.m., the program announcement at 8:00 p.m. To register, please visit http://www.abiomed.com/news/TCT2007Symposium.cfm.

The Impella 2.5 is the world's smallest ventricular assist device (VAD) which provides patients with up to 2.5 liters of blood flow per minute and has been used under CE Mark approval in Europe to treat conditions such as acute myocardial infarction (heart attack), cardiogenic shock, and low output syndrome. Due to a rise in conditions such as triple vessel disease in patients with poor cardiac function, which is caused by coronary vessel blocks in three vessels of the heart, the Impella 2.5 provides a new treatment option that aims to improve patient outcomes. The Impella 2.5 is currently the subject of pivotal trials in the United States and has not yet been approved by the FDA.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com.

FORWARD-LOOKING STATEMENTS

This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including the Company's ability to provide the FDA with the additional information it has requested, the results of the Company's pivotal study, uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the risk factors contained in the Company's Annual Report filed on Form 10-K and recently filed Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.